oseltamivir has been researched along with everolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hodge, TW; McDonald, NJ; Murray, JL; O'Brien, WA; Rubin, DH; Shaw, MW; Sheng, J; Smee, DF | 1 |
1 review(s) available for oseltamivir and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for oseltamivir and everolimus
| Article | Year |
|---|---|
Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis.
Topics: Animals; Antiviral Agents; Cell Line; Everolimus; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mutagenesis, Insertional; Oseltamivir; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA Interference; Sirolimus; TOR Serine-Threonine Kinases; Virus Replication | 2012 |